Carbon dioxide laser therapy for the management of genitourinary syndrome of menopause: A meta‑analysis of randomized controlled trials

Ni,Yihua; Lian,Junyu

doi:10.3892/etm.2023.12297

Carbon dioxide laser therapy for the management of genitourinary syndrome of menopause: A meta‑analysis of randomized controlled trials

Authors:
- Yihua Ni
- Junyu Lian
View Affiliations

Affiliations: Department of Gynecology, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian 350001, P.R. China
Published online on: November 13, 2023 https://doi.org/10.3892/etm.2023.12297
Article Number: 10
Copyright : © Ni et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Genitourinary symptoms of menopause (GSM) affect ~50% of women after menopause. Recently, CO₂ laser therapy has been used for managing GSM but without high quality evidence. The present review assessed the effectiveness of CO₂ laser therapy in the management of GSM. PubMed, Embase, Web of Science, CENTRAL and Scopus databases were searched for randomized controlled trials (RCTs), published up to June 30, 2023, comparing CO₂ laser and sham laser treatments for GSM management. The outcomes of interest included Female Sexual Function Index (FSFI), Vaginal Health Index (VHI) and visual analog scale (VAS) for dyspareunia, dryness, burning, itching and dysuria. A total of seven RCTs were included in the review and meta‑analysis, with 6/7 studies using three sessions of laser therapy, 4‑8 weeks apart. Meta‑analysis demonstrated no statistically significant difference in FSFI [mean difference (MD), ‑1.48; 95% CI, ‑5.85, 2.89; I²=45%] and VHI scores (MD, ‑0.18; 95% CI, ‑1.66, 1.31; I² =72%) between laser and control groups. Meta‑analysis also demonstrated no statistically significant difference in VAS scores for dyspareunia (MD, ‑1.63; 95% CI; ‑4.06, 0.80; I2=91%), dryness (MD, ‑1.30; 95% CI, ‑3.14, 0.53; I²=75%), burning (MD, ‑0.76; 95% CI, ‑2.03; 0.51 I²=56%), itching (MD, ‑0.28; 95% CI, ‑0.95, 0.38; I²=0%) and dysuria (MD, 0.15; 95% CI, ‑0.37, 0.67; I²=23%) between the groups. The included RCTs had low risk of bias. In conclusion, meta‑analyses of high‑quality sham‑controlled RCTs indicated that CO₂ may not have any beneficial effect on GSM. Limited data and high heterogeneity in meta‑analyses in this area of research are important limitations that need to be addressed by future RCTs.

View Figures

View References

1	Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B and Khan SA: Genitourinary syndrome of menopause: An overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 215:704–711. 2016.PubMed/NCBI View Article : Google Scholar
2	Parish SJ, Nappi RE, Krychman ML, Kellogg-Spadt S, Simon JA, Goldstein JA and Kingsberg SA: Impact of vulvovaginal health on postmenopausal women: A review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 5:437–447. 2013.PubMed/NCBI View Article : Google Scholar
3	Mac Bride MB, Rhodes DJ and Shuster LT: Vulvovaginal atrophy. Mayo Clin Proc. 85:87–94. 2010.PubMed/NCBI View Article : Google Scholar
4	North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 14:357–369. 2007.PubMed/NCBI View Article : Google Scholar
5	Benini V, Ruffolo AF, Casiraghi A, Degliuomini RS, Frigerio M, Braga A, Serati M, Torella M, Candiani M and Salvatore S: New innovations for the treatment of vulvovaginal atrophy: An up-to-date review. Medicina (Kaunas). 58(770)2022.PubMed/NCBI View Article : Google Scholar
6	Radnia N, Hosseini S, Vafaei S, Pirdehghan A and Mehrabadi N: The effect of conjugated estrogens vaginal cream and a combined vaginal cream of vitamins D and E in the treatment of genitourinary syndrome. J Fam Med Prim Care. 12(507)2023.PubMed/NCBI View Article : Google Scholar
7	Rabley A, O'Shea T, Terry R, Byun S and Louis Moy M: Laser therapy for genitourinary syndrome of menopause. Curr Urol Rep. 19(83)2018.PubMed/NCBI View Article : Google Scholar
8	Filippini M, Porcari I, Ruffolo AF, Casiraghi A, Farinelli M, Uccella S, Franchi M, Candiani M and Salvatore S: CO₂-Laser therapy and genitourinary syndrome of menopause: A systematic review and meta-analysis. J Sex Med. 19:452–470. 2022.PubMed/NCBI View Article : Google Scholar
9	Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ and Welch VA (eds): Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. John Wiley & Sons, Chichester, UK, 2019.
10	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg. 88(105906)2021.PubMed/NCBI View Article : Google Scholar
11	Quick AM, Dockter T, Le-Rademacher J, Salani R, Hudson C, Hundley A, Terstriep S, Streicher L, Faubion S, Loprinzi CL, et al: Pilot study of fractional CO₂ laser therapy for genitourinary syndrome of menopause in gynecologic cancer survivors. Maturitas. 144:37–44. 2021.PubMed/NCBI View Article : Google Scholar
12	Page AS, Verbakel JY, Verhaeghe J, Latul YP, Housmans S and Deprest J: Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial. BJOG. 130:312–319. 2023.PubMed/NCBI View Article : Google Scholar
13	Li FG, Maheux-Lacroix S, Deans R, Nesbitt-Hawes E, Budden A, Nguyen K, Lim CY, Song S, McCormack L, Lyons SD, et al: Effect of fractional carbon dioxide laser vs. sham treatment on symptom severity in women with postmenopausal vaginal symptoms: A randomized clinical trial. JAMA. 326:1381–1389. 2021.PubMed/NCBI View Article : Google Scholar
14	Mension E, Alonso I, Anglès-Acedo S, Ros C, Otero J, Villarino Á, Farré R, Saco A, Vega N, Castrejón N, et al: Effect of fractional carbon dioxide vs. sham laser on sexual function in survivors of breast cancer receiving aromatase inhibitors for genitourinary syndrome of menopause: The LIGHT randomized clinical trial. JAMA Netw Open. 6(E2255697)2023.PubMed/NCBI View Article : Google Scholar
15	Cruff J and Khandwala S: A double-blind randomized sham-controlled trial to evaluate the efficacy of fractional carbon dioxide laser therapy on genitourinary syndrome of menopause. J Sex Med. 18:761–769. 2021.PubMed/NCBI View Article : Google Scholar
16	Salvatore S, Pitsouni E, Grigoriadis T, Zacharakis D, Pantaleo G, Candiani M and Athanasiou S: CO₂ laser and the genitourinary syndrome of menopause: A randomized sham-controlled trial. Climacteric. 24:187–193. 2021.PubMed/NCBI View Article : Google Scholar
17	Ruanphoo P and Bunyavejchevin S: Treatment for vaginal atrophy using microablative fractional CO₂ laser: A randomized double-blinded sham-controlled trial. Menopause. 27:858–863. 2020.PubMed/NCBI View Article : Google Scholar
18	Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 20:888–902. 2013.PubMed/NCBI View Article : Google Scholar
19	Kingsberg SA and Krychman ML: Resistance and barriers to local estrogen therapy in women with atrophic vaginitis. J Sex Med. 10:1567–1574. 2013.PubMed/NCBI View Article : Google Scholar
20	Salvatore S, Maggiore ULR, Athanasiou S, Origoni M, Candiani M, Calligaro A and Zerbinati N: Histological study on the effects of microablative fractional CO₂ laser on atrophic vaginal tissue: An ex vivo study. Menopause. 22:845–849. 2015.PubMed/NCBI View Article : Google Scholar
21	Zerbinati N, Serati M, Origoni M, Candiani M, Iannitti T, Salvatore S, Marotta F and Calligaro A: Microscopic and ultrastructural modifications of postmenopausal atrophic vaginal mucosa after fractional carbon dioxide laser treatment. Lasers Med Sci. 30:429–436. 2015.PubMed/NCBI View Article : Google Scholar
22	Perino A, Calligaro A, Forlani F, Tiberio C, Cucinella G, Svelato A, Saitta S and Calagna G: Vulvo-vaginal atrophy: A new treatment modality using thermo-ablative fractional CO₂ laser. Maturitas. 80:296–301. 2015.PubMed/NCBI View Article : Google Scholar
23	U.S. Food and Drug Administration: Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to safeguard women's health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for ‘vaginal rejuvenation’. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims#:~:text=We%20are%20deeply%20concerned%20women,as%20condylomas%20(genital%20warts). Accessed June 30, 2023.
24	Gorayeb RP, Forjaz MJ, Ferreira AG and Ferreira JJ: Use of sham interventions in randomized controlled trials in neurosurgery. J Neurol Surg A Cent Eur Neurosurg. 81:456–462. 2020.PubMed/NCBI View Article : Google Scholar
25	D'Oria O, Giannini A, Buzzaccarini G, Tinelli A, Corrado G, Frega A, Vizza E and Caserta D: Fractional CO₂ laser for vulvo-vaginal atrophy in gynecologic cancer patients: A valid therapeutic choice? A systematic review. Eur J Obstet Gynecol Reprod Biol. 277:84–89. 2022.PubMed/NCBI View Article : Google Scholar
26	Khamis Y, Abdelhakim AM, Labib K, Islam BA, Nassar SA, Motaal AOA, Saleh DM, Abdou H, Abbas AM and Mojahed EM: Vaginal CO₂ laser therapy versus sham for genitourinary syndrome of menopause management: A systematic review and meta-analysis of randomized controlled trials. Menopause. 28:1316–1322. 2021.PubMed/NCBI View Article : Google Scholar
27	Seav SM, Dominick SA, Stepanyuk B, Gorman JR, Chingos DT, Ehren JL, Krychman ML and Su HI: Management of sexual dysfunction in breast cancer survivors: A systematic review. Womens Midlife Health. 1(9)2015.PubMed/NCBI View Article : Google Scholar
28	Vizza R, Capomolla EM, Tosetto L, Corrado G, Bruno V, Chiofalo B, Di Lisa FS, Filomeno L, Pizzuti L, Krasniqi E, et al: Sexual dysfunctions in breast cancer patients: Evidence in context. Sex Med Rev. 11:179–195. 2023.PubMed/NCBI View Article : Google Scholar
29	Gordon C, Gonzales S and Krychman ML: Rethinking the techno vagina: A case series of patient complications following vaginal laser treatment for atrophy. Menopause. 26:423–427. 2019.PubMed/NCBI View Article : Google Scholar
30	Ahluwalia J, Avram MM and Ortiz AE: Lasers and energy-based devices marketed for vaginal rejuvenation: A cross-sectional analysis of the MAUDE database. Lasers Surg Med. 51:671–677. 2019.PubMed/NCBI View Article : Google Scholar